Empowering Global Health: The Journey to GMP-Ready mRNA Manufacturing

WEBINAR

Join us for a webinar on the WHO/MPP-led mRNA Technology Transfer Programme, highlighting the GMP-ready filtration process for the AfriVac 2121 vaccine. We'll discuss the challenges and collaborative efforts in mRNA purification, and how these advancements promote global health equity and pandemic preparedness.

This webinar intends to share the development of a GMP-ready filtration production process under the WHO/MPP mRNA Technology Transfer Programme, focusing on the development of the AfriVac 2121 vaccine candidate in collaboration with Afrigen Biologics, the Center of Excellence in this Programme.

Key technical insights will be presented, including the optimization of tangential flow filtration (TFF) processes, which transitioned from R&D scale to 100 mL and then to 1 L IVT (in-vitro transcription) scale. Trials demonstrated the effectiveness of TFF filters with 300 kDa regenerated cellulose membranes, enhancing product recovery while maintaining mRNA integrity, with robust scaling outcomes.

Additionally, the importance of bioburden control filtration will be discussed, emphasizing the use of Milligard^® PES and Millipore Express^® SHC filters, which consistently achieved over 95% recovery while preserving mRNA integrity.

These advancements not only facilitate GMP-readiness for mRNA vaccines and therapeutics but also contribute to global health equity by establishing sustainable production capabilities in Low- and Middle-Income Countries (LMICs), positioning us better for future pandemic preparedness.

In this webinar, you will learn about:

• the key purification challenges in mRNA manufacturing met in the programme.
• the collaborative efforts between MilliporeSigma and Afrigen in developing GMP-ready purification processes, with optimization and robust scale-up implementation.